click below
click below
Normal Size Small Size show me how
obesity
obesity medications
name | common names | side effects | dose | contraindications | Drug class | action |
---|---|---|---|---|---|---|
meformin | common brands: glucophage, riomet, glumetza, glucophage xr, and fortamet | diarrhea, nausea, vomiting and flatulence | once or twice daily: available immediate release (500mg, 850mg, and 1000mg) and extended release (500mg and 1000mg), Max dose 2500mg/day | severe kidney disease (eGFR<30ml/minute/1.73m^2 metabolic acidosis, or diabetic ketoacidosis caution: experiencing muscle aches, abdominal pain; monitor b12 periodically with long term therapy | Non-sulfonylureas | diabetes patients. It reduces glucose absorption from the intestines, lowers liver glucose production, and improves insulin sensitivity. Improves insulin sensitivity, decreases blood glucose levels, decreases appetite, decreases body fat |
Ozempic | Semaglutide | Nausea, fatigue, HA, dizziness, vomiting, upset stomach, diarrhea, constipation | SQ Weekly week 1-4: 0.25mg week 5-8: 0.5mg week 9-12: 1mg week 13 and after: 2mg | caution: pancreatitis, and patients on diabetes medicine (insulin, sulfonylurea; Family or person history of medullary thyroid cancer or multiple endocrine neoplasia syndrome; nursing or pregnant women | GLP-1 receptor agonist | indicated for diabetes; it decreases hunger and increases fullness |
Wegovy | Semaglutide | Nausea, fatigue, HA, dizziness, vomiting, upset stomach, diarrhea, constipation, heartburn | SQ Weekly week 1-4: 0.25mg week 5-8: 0.5mg week 9-12: 1mg week 13-16: 1.7mg week 17 and afterward: 2.4mg | caution: pancreatitis, and patients on diabetes medicine (insulin, sulfonylurea; Family or person history of medullary thyroid cancer or multiple endocrine neoplasia syndrome; nursing or pregnant women | GLP-1 receptor agonist | indicated for BMI >/=27 and one additional obesity related condition (sleep apnea, HTN, DM, high cholesterol) or BMI >/= 30; it decreases hunger and increases fullness |
Mounjaro | tirzepatide | Decrease appetite, nausea, diarrhea, vomiting, constipation, dyspepsia | GLP-1 receptor agonist and GIP (glucose dependent insulinotropic polypeptide | |||
Saxenda | Liraglutide | Nausea, fatigue, HA, dizziness, vomiting, upset stomach, diarrhea, constipation | SQ Daily week 1: 0.6mg week 2: 1.2mg week 3: 1.8mg week 4: 2.4mg week 5 and afterward: 3.0mg | caution: pancreatitis, and patients on diabetes medicine (insulin, sulfonylurea; Family or person history of medullary thyroid cancer or multiple endocrine neoplasia syndrome; nursing or pregnant women | GLP-1 receptor agonist | indicated for BMI >/=27 and one additional obesity related condition (sleep apnea, HTN, DM, high cholesterol) or BMI >/= 30; it decreases hunger and increases fullness |
Zoloft | sertraline | Nausea, dizziness, drowsiness, dry mouth, loss of appetite, increased sweating, diarrhea, upset stomach, or trouble sleeping may occur | may affects the heart rhythm (QT prolongation). | antidepressant | ||
Topamax or N | Topiramate | metallic or flat taste to carbonated beverages, word finding difficulties, numbness and tingling in hands/feet, problems with mood, concentration/attention | Take po medication in afternoon; starting dose 25mg. Dose may be titrated 25mg every 2-4 wees. Typical dose 25-100mg/day | Kidney stones; glaucoma; Taking topiramate during pregnancy may increase the risk of cleft lip and/or cleft palate, a birth defect that can develop early in pregnancy | Carbonic anhydrase inhibitor anticonvulsants | for obesity: unknown; Through past studies have shown it may decrease hunger or have a role in how fat is stored in the body Normally used for migraines, seizures |
phentermine or Diethylpropion | Adipex-P; Lomaira | heart palpitations, anxiety, HTN, nausea, dry mouth (xerostomia), dizziness | take 8mg table daily tid 30 minutes prior to meal; or 15-37.5mg once daily before breakfast; some cases may administer 18.75mg once to twice daily. | patient with history of cardiovascular disease, drug abuse, pregnancy, hyperthyroidism or within 14 days of MAOI inhibitor therapy | CNS stimulant; sympathomimetrics | weight loss by decreasing appetite |
bupropion | ||||||
victoza | ||||||
Vyvanse *FDA approved for binge eating disorder | LIsdexamfetamine | reduces bunge-eating and related obsessions and compulsions | ||||
Zepbound | tirzepatide | GLP-1 receptor agonist and GIP (glucose dependent insulinotropic polypeptide | indicated for BMI >/=27 and one additional obesity related condition (sleep apnea, HTN, DM, high cholesterol) or BMI >/= 30; it decreases hunger and increases fullness | |||
Qsymia (phentermine/topiramate) | ||||||
Contrave (Naltrexone ER/ Bupropion ER) | ||||||
Plenity |